Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - Defendants allegedly made unauthorized design changes to the G6 and G7 systems that compromised their reliability and safety [2]. - The enhancements claimed for the G7 device were reportedly overstated, leading to potential health risks for users relying on these devices for accurate glucose readings [2]. - DexCom is accused of downplaying the severity of issues related to the G7 devices, which could result in increased regulatory scrutiny and significant legal and financial repercussions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the enhancements to the G7 device were overstated, and the true scope of issues related to the G7 devices was downplayed by the defendants [5]. - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [5].

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form-2 ...

DXCM DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - DXCMDecember 05, 2025 2:05 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (t ...

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DexCom, Inc. (NASDAQ:DXCM) and Wildermuth Fund (NASDAQ:WEFCX, NASDAQ:WESFX. NASDAQ:WEIFX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. DexCom, Inc. (NASDAQ:DXCM) Class Period: ...

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability [2]. - The design changes reportedly posed a material health risk to users who relied on these devices for accurate glucose readings [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, while downplaying the severity of issues related to adulterated devices [2]. - The company faces increased regulatory scrutiny and potential legal, reputational, and financial harm due to these allegations [2]. Group 2: Legal Process for Investors - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and selects counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].

NEW YORK, Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=179561&from=4CLASS PERIOD: January 8, 2024 to Septembe ...

Speaking about Dexcom's approach, Maite Penalba, President of the Association for Diabetes Educators, Valencia, added: "Through Dexcom Academy, healthcare professionals can access training that offer us certification, that we can manage at our own pace, and that add value because they are based on real case studies. "The courses not only facilitate an understanding of the [CGM] system's features but can also be practically applied in consultations with people with diabetes. Dexcom Academy is an opportunity ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its Dexcom G7 continuous glucose monitoring system, impacting investors who purchased shares between January 8, 2024, and September 17, 2025 [4][5]. Group 1 - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who acquired DexCom securities during the specified period [4]. - Allegations include that the company and certain senior officers made false statements about the device's reliability and enhancements, as well as the expansion of manufacturing capabilities [5]. - Investors interested in participating as lead plaintiffs must file by December 26, 2025, although participation in any recovery does not require serving as lead plaintiff [6]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [7].

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $24.8 billion by market cap, the company develops a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin and a small external receiver to which the sensor transmits glucose levels at specified intervals. Companies worth $10 billion or more are generally described as “large-cap s ...